Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
Reiffel
J A
JA
Electrophysiology Service, Division of Cardiology, Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, USA.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000592:standards* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods*; D016568:Drugs, Generic / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D006827:Hydantoins; D007093:Imidazoles / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D048289:Imidazolidines; D010627:Phenethylamines / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D013015:Sotalol / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
D000889:Anti-Arrhythmia Agents; D016568:Drugs, Generic; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; D010627:Phenethylamines; D010879:Piperazines; D013449:Sulfonamides; C086123:azimilide; D013015:Sotalol; C063533:dofetilide